Final overall survival (OS) analysis of COU-AA-301, a phase 3 study of abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) pretreated with docetaxel

Category Primary study
JournalEuropean Journal of Cancer
Year 2011
This article has no abstract
Epistemonikos ID: 79b0efe53934e098ad64fabe0a94c6e93afeba2f
First added on: Feb 04, 2025